BlueWind Medical

Neuromodulation Therapy for Urge Urinary Incontinence

Health Tech & Life Sciences
Private

Company Overview

Snapshot

Founded in December 2010, BlueWind Medical operates with 51–200 employees and has raised a total of $111.8 million across two funding rounds. The company secured $47.8 million in May 2026 to accelerate the commercialization of its Revi System.

Business overview

BlueWind Medical is an innovative medical device company focused on transforming neuromodulation therapy for urge urinary incontinence (UUI). The company has developed Revi, a miniature implantable device designed to eliminate the need for replacement surgeries due to battery changes, lead migration, or lead fracture. Its technology includes an external wearable component that powers the implant, offering a patient-centric approach with flexible energy and stimulation sessions. BlueWind Medical serves the healthcare industry, specifically targeting providers and patients within the medical devices, medical treatment, and therapeutics sectors.

Strategic signal

In May 2026, BlueWind Medical secured $47.8 million in financing, a significant capital injection aimed at accelerating the commercialization of its Revi System. This funding signals strong investor confidence in the company's innovative neuromodulation technology and its potential to address urge urinary incontinence, positioning BlueWind Medical for expanded market penetration and broader patient access in the near future.

Company Intelligence Q&A

What was the most recent funding event for BlueWind Medical?
In May 2026, BlueWind Medical secured $47.8 million in financing to accelerate the commercialization of its Revi System.
Which investors participated in BlueWind Medical's May 2022 funding round?
In May 2022, BlueWind Medical raised $64 million in a funding round that included investments from ConvaTec and Medtronic.
When did BlueWind Medical's Revi System receive US FDA De Novo Classification?
BlueWind Medical's Revi System secured U.S. FDA De Novo Classification Grant for the treatment of urgency incontinence in August 2023.
What key milestone did BlueWind Medical achieve regarding CPT codes?
In March 2023, BlueWind Medical announced that the AMA issued a unique Category III CPT code for subfascial placement of tibial neurostimulators, a key milestone for its technology.
When did BlueWind Medical bring its Revi implantable tibial neuromodulation device to Shreveport, Louisiana?
In December 2023, BlueWind Medical brought its Revi implantable tibial neuromodulation device to patients in Shreveport, Louisiana.

External links